Glicaneed 60 MR Tablet contains Gliclazide 60mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. The modified-release (MR) formulation ensures a sustained release of the active ingredient, allowing for once-daily dosing and maintaining stable plasma concentrations over an extended period, which enhances patient compliance and reduces the risk of hypoglycemic episodes. Glicaneed 60 MR is typically prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Dose adjustments may be necessary based on clinical response and renal function. Patients should be advised to recognize symptoms of hypoglycemia and maintain regular follow-up with their healthcare provider to optimize therapeutic outcomes and minimize potential risks associated with therapy.